🔗 Share this article

Elected officials have expressed alarm that the United Kingdom's recent agreements with Donald Trump are "lacking a solid foundation." This stems from revelations that a much-touted deal on pharmaceutical tariffs, which commits to zero tariffs in exchange for the NHS facing higher prices, lacks any underlying contract beyond broad headline terms outlined by government press releases.

A Deal Without Detail

The arrangement concerning medicines, hailed as a "landmark" achievement, exists as an "agreement in principle" without detailed provisions. Observers point out that the press releases from the UK and US governments present the deal in markedly contrasting terms. The British version celebrates securing "duty-free access" as a singular success, while the American announcement concentrates on the expectation for the NHS to pay higher prices for new medications.

"We face a genuine possibility that the UK government has promised concessions to raise drug prices in return for little more than a pledge from President Trump," commented David Henig, a trade expert. "We know he has a tendency for not following through on agreements."

Broader Instability and a Paused Tech Deal

Concerns have been amplified by Washington's recent decision to suspend the £31bn "tech prosperity deal", which was previously heralded as "a transformative pact" in the bilateral relationship. The US pointed to a lack of progress from the UK on reducing other tariffs as the reason for the pause.

Furthermore, concessions secured for British farmers as part of an initial accord have not been formally ratified by the US, despite a looming January deadline. "We have been informed that that the US has failed to approve the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have expressed concerns that the government's deals with Washington are unstable and unpredictable. One minister reportedly said the series of agreements as "resting on shaky ground," while another characterized the situation as the "current reality" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, argued: "Perhaps most shocking than Trump's temper tantrums is the UK government's naive belief that his administration is a reliable partner. The NHS is too precious to be gambled with."

Government Downplays Risks, Points to Gains

Ministry sources have sought to reduce the risk of the US reneging on the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been pushing for the agreement, seeking certainty on imports and pricing, making it more concrete than the paused tech deal.

Officials admit that instability is inherent in dealing with the current US leadership. However, they contend that the UK has obtained tangible results for businesses, such as reduced duties on automobiles compared to other nations. "Our achievement of 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a solid gain," one official said.

Nevertheless, issues have emerged in implementing the broader trade deal. Promised reciprocal agricultural allowances have yet to be finalized, and the pledge to "remove tariffs on British steel and aluminium" has is still pending, with tariffs staying at 25%.

Looking ahead, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.